Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDYMION 2 long-term open-label extension of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome
2022-502802-34-00Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome (LGS) (2 cohorts), sponsored by Takeda. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of abnormal laboratory and ECG values and 4 more. Started Feb 2024; status: completed.
02
Drugs
soticlestat
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2022-502802-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502802-34-00.